Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.
Castro-Marrero, Jesus, Sáez-Francàs, Naia, Santillo, Dafna et al. · British journal of pharmacology · 2017 · DOI
Quick Summary
This review looked at all available research on treatments for ME/CFS to see what actually helps patients. The researchers found that while some treatments like behavioral therapy, pacing strategies, and nutritional supplements show promise, the evidence is still limited because most studies were small and used different methods. The authors conclude that personalized pacing and treating nutritional deficiencies are reasonable approaches, but much larger and better-designed studies are urgently needed to know what really works.
Why It Matters
ME/CFS patients lack FDA-approved treatments and established diagnostic biomarkers, making evidence-based clinical guidance critical. This review synthesizes what is known about treatment options and clearly identifies the urgent need for better research, helping patients understand why definitive treatment recommendations remain elusive and advocating for the rigorous studies necessary to advance patient care.
Observed Findings
Rintatolimod and rituximab showed potential benefits in some studies, though evidence remains limited
Counseling, behavioral therapy, and rehabilitation programs demonstrated some benefit in preliminary research
Adaptive pacing strategies offered symptom relief in some patients, though results are debatable
Nutritional supplementation may benefit patients with biochemically proven deficiencies
Existing trials were small-scale with high risk of bias and used inconsistent ME/CFS case definitions
Inferred Conclusions
Personalized pacing programs and nutritional supplementation for patients with documented deficiencies represent reasonable treatment approaches pending stronger evidence
No firm conclusions about treatment effectiveness can be drawn from current literature due to methodological limitations
Larger, rigorously designed randomized controlled trials are urgently needed to identify effective treatments
Future trials must stratify outcomes by clinical presentation, patient characteristics, case criteria, and disability severity (including severely ill and bedridden patients)
Remaining Questions
Which specific treatments are most effective for different subgroups of ME/CFS patients based on symptom presentation or severity?
What This Study Does Not Prove
This review does not prove that any single treatment is effective for ME/CFS—it only identifies which treatments have been studied and notes that evidence is limited. The heterogeneous nature of existing studies means results cannot be directly compared, so this review cannot establish which interventions work best for which patients or population subgroups. It also does not determine whether observed benefits persist long-term or generalize across different ME/CFS presentations.